Leadership

Co-Founder, Chief Executive Officer and Chief Scientific Officer

Chief Financial Officer

Sigal Fattal has a track record of over 20 years of extensive experience in establishing and managing financial, operational, and business activities in a wide range of companies and industries, both locally and globally, including experience in leading IPOs, private investment and M&A transactions. Ms. Fattal started her career as Director of Finance of ECtel, where she played a key role in growing the company into a large-scale global entity and completing a successful IPO. At BiomX, she helped structure and manage day to day corporate activity and set strategic direction, as well as spearheading the public its merger with a public company. Earlier, Ms. Fattal served as the CFO of Evogene, where she developed and managed the company's corporate structure and led its successful U.S. IPO. She is a certified CPA (Isr.), holds a BA in Accounting and Economics, with honors, and an MBA, both from Tel Aviv University.

Interim Chief Medical Officer

David Weiner has 30 years’ experience in the discovery and development of novel therapeutics. He is currently Chief Scientific Officer and a director at AxoSIm, Inc. and a director at Bright Minds and Novoron. Previously he served in multiple leadership roles in neurology and rare disease-focused biotechnology companies, including Chief Executive Officer of Amathus Therapeutics and Chief Medical Officer at Lumos Pharma, aTyr Pharma and Proteostasis Therapeutics. Earlier in his career, Dr. Weiner held key drug development roles at EMD/Merck Serono and spent a decade in discovery research and clinical development at Acadia Pharmaceuticals. Dr. Weiner received a BA degree cum laude with highest honors from Brandeis University and an MD degree from the School of Medicine and Biomedical Sciences, SUNY Buffalo. He did a post-doctoral fellowship in neuropharmacology at the University of Vermont and was a Howard Hughes Medical Institute Research Scholar. Dr. Weiner has co-authored over 30 scientific publications and multiple patents. He serves as a director, consultant and scientific and clinical advisory board member to biotechnology companies and foundations, including the Michael J. Fox Foundation for Parkinson’s Research.

Chief Development Officer

Mr. Lawler joined Chemomab in January of 2022 with more than 22 years of successful drug development experience. Prior to joining Chemomab, Mr. Lawler served on the Senior Leadership team as Vice President, Clinical Operations and Data Management at Goldfinch Bio. Prior to Goldfinch Bio, Mr. Lawler has held a series of drug development positions at several small and mid-size biotechnology companies and participated in the drug development for eight approved pharmaceutical products at Teva (Cephalon), Trevena, Shire (Viropharma) and Egalet. He  earned a Bachelor of Science in Business Management from Rosemont College.

Vice President, Translational Science

Dr. Revital Aricha joined Chemomab in May 2022 with more than two decades of translational research experience in a wide variety of scientific fields. Previously Dr. Aricha served as Vice President of Research and Development at Brainstorm-Cell Therapeutics. In this role, she was instrumental in drug development, providing scientific support for advanced clinical trials and developing biomarker strategies. Earlier, Dr. Aricha was a senior scientist at the Department of Immunology of the Weizmann Institute of Science, where she specialized in novel treatments for autoimmune diseases. She received BA and  MA degrees from Bar-Ilan University, where she also received her PhD in Neuroimmunology summa cum laude. Dr. Aricha completed a postdoctoral fellowship at the Weizmann Institute of Science.

Consulting Vice President Strategic Communications, Investor & Public Relations

Barbara Lindheim has been providing strategic communications services to the biotechnology and life sciences industries for 30 years, helping industry innovators achieve optimal positioning, compelling messaging and highly relevant content. She is also a principal at BLL Partners, LLC, and previously held senior communications and strategy roles at Orchid BioSciences, Edelman Public Relations, BioCom Partners, Noonan/Russo Communications, Glaxo SmithKline, Pfizer and Sanofi. Earlier in her career, Ms. Lindheim developed strategy and advocacy programs for non-profit and government organizations. An Honors graduate of Cornell University, Ms. Lindheim earned an MBA with distinction from Harvard Business School and an MPA degree in public policy from Princeton University. She lectures on biomedical industry strategy at leading business schools.